AX-2026-043498

MOTS-c · 5 mg declared · Qingdao Saber Technology Pharmaceutical · lot QST-2511-H5351

PASSIDENTITY CONSISTENT

Report ID: AX-2026-043498
Compound: MOTS-c
Compound class: Metabolic and mitochondrial peptides
Supplier: QST — Qingdao Saber Technology Pharmaceutical
Batch / lot: QST-2511-H5351
Declared label claim: 5mg
Laboratory: Kestrel Bioanalytical
Assay date: 06 May 2026
Submitted: 27 May 2026
Quarter: 2026-Q2
Submitter: h.yilmaz
Sample provenance: Buyer-sourced

Section 1

Results

Measured against the index acceptance specification for the metabolic and mitochondrial peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 15 min gradient, 214 nm	98.36	% area	≥ 98.0	PASS
Total impurities	RP-HPLC, sum of reported peaks	1.64	% area	≤ 2.0	PASS
Largest single impurity	RP-HPLC — des-Met1 (−131 Da)	0.70	% area	≤ 1.00	PASS
Identity — theoretical monoisotopic mass	calculated from molecular formula	2173.0918	Da	—	NOT TESTED
Identity — observed monoisotopic mass	LC-MS, unit resolution (single quadrupole)	2173.1181	Da	—	NOT TESTED
Mass accuracy	observed vs theoretical	+12.1	ppm	± 15	PASS
Peptide content	not ordered on this submission	not determined	—	required to check label claim	NOT TESTED
Water content	Karl Fischer, coulometric, duplicate	5.08	%	≤ 9.0	PASS
Counter-ion (acetate)	anion-exchange ion chromatography	5.63	%	≤ 12.0	PASS
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.16	%	—	NOT TESTED
Endotoxin	kinetic chromogenic LAL	0.45	EU/mg	≤ 5.0	PASS
Sterility	not ordered on this submission	not determined	—	no growth	NOT TESTED
Appearance	visual, diffuse light, black and white background	White lyophilised cake, intact	—	white to off-white intact cake	PASS
Reconstitution clarity	reconstituted per submitter procedure	Clear, colourless, no visible particulates	—	clear, no visible particulates	PASS
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	5.57	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 15 min gradient	5.53	min	5.63 ± 0.30 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	1.24	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	43,142	—	≥ 20,000	PASS
Resolution to nearest impurity	vs des-Met1 (−131 Da)	1.01	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 15 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 43,142, and skew follows the reported asymmetry factor of 1.24. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.70 % impurity against a 98.36 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	MOTS-c — main peak	5.53	4,780,601	98.36	—
2	des-Met1 (−131 Da)	5.64	34,022	0.70	-131.040
3	bis-sulfoxide (+32 Da)	5.20	26,246	0.54	+31.990
4	deamidated (+1 Da)	5.38	10,207	0.21	+0.984
5	Met1 sulfoxide (+16 Da)	5.34	9,235	0.19	+15.995
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 3

Mass spectrum and identity

Theoretical monoisotopic mass 2173.0918 Da, computed from C101H152N28O22S2. All ppm figures on this site are against monoisotopic values — see why that matters.

Figure 2. ESI charge-state envelope, unit-resolution instrument. Sticks are placed at m/z = (M + z × 1.007276)/z for the observed neutral mass of 2173.1181 Da. Sodium (+21.982/z) and potassium (+37.956/z) adducts are shown where the parent charge state exceeds 25 % relative abundance; they are adducts of the same molecule and are not impurities.

Charge	Theoretical m/z	Observed m/z	Δ m/z	Rel. abundance (%)
4+	544.2802	544.2868	0.0066	9.3
3+	725.3712	725.3800	0.0088	57.6
2+	1087.5532	1087.5663	0.0131	100.0
1+	2174.0991	2174.1254	0.0263	54.2

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	98.29	98.36	divergence -0.07 pp vs batch median
Total impurities (% area)	1.71	1.64
Largest single impurity (% area)	0.85	0.70
Water (%)	not stated	5.08
Counter-ion (%)	not stated	5.63
Peptide content (%w/w)	not stated	not determined
Endotoxin (EU/mg)	not stated	0.45
Method stated on certificate	YES	—	column, gradient and wavelength given

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Buyer-sourced
Evidentiary weight: Strongest available evidence in this index.
Chain of custody: Retail purchase → submitter (−20 °C, 30 d) → laboratory (courier, dry ice, 9 d) → assay.
Assay date: 06 May 2026
Submitted to the index: 27 May 2026
Laboratory: Kestrel Bioanalytical, Melbourne, Australia
Method basis: 15 min gradient · unit-resolution MS
Verification status: IDENTITY CONSISTENT

What this report does not establish

That the compound is not a near-isobaric alternative. Identity was confirmed at unit mass resolution, which cannot exclude species differing by 1 or 2 Da. The specific alternatives not excluded are named in the identity block above.
How much of the named compound is in the vial. Peptide content was not determined, so recovered mass cannot be calculated and the label claim cannot be checked.
That the material is sterile. Sterility was not tested.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations 2

Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.

plate_count27 May 2026

Efficiency is the lever that does not change selectivity, so it improves resolution without moving anything else. Longer column, smaller particle, or lower flow, in that order of cost.

cell_sparsity27 May 2026

Matrix occupancy on this compound is low. Every additional record moves the median visibly, which is the definition of a cell that should not be quoted.

Section 7

Related records

Same batch — lot QST-2511-H5351 n=1

This is the only report on this lot. One report is not a batch characterisation.

Batch rollup and reproducibility assessment →

Cross-sections

Other recent MOTS-c records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-042083	HYB	HYB-2606-D7858	Medutest	2026-Q3	99.93	2.02	—	Buyer-sourced	0	PASS
AX-2026-042090	HYB	HYB-2606-D7858	Janoshik	2026-Q3	99.57	2.36	—	Buyer-sourced	1	FAIL
AX-2026-042084	HYB	HYB-2606-D7858	Janoshik	2026-Q3	99.28	2.79	107.3	Buyer-sourced	0	PASS
AX-2026-042087	HYB	HYB-2606-D7858	Janoshik	2026-Q3	99.54	3.05	—	Buyer-sourced	0	PASS
AX-2026-042085	HYB	HYB-2606-D7858	Janoshik	2026-Q3	99.51	2.31	—	Buyer-sourced	0	PASS
AX-2026-042088	HYB	HYB-2606-D7858	PeptideMeter	2026-Q3	99.22	2.21	—	Buyer-sourced	0	PASS
AX-2026-042086	HYB	HYB-2606-D7858	Janoshik	2026-Q3	99.93	3.02	—	Buyer-sourced	1	MARGINAL
AX-2026-042081	HYB	HYB-2606-D7858	Nordanalyt	2026-Q3	99.68	3.31	96.5	Laboratory-retained	0	PASS

Other recent QST records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-043497	GHRP-6	QST-2508-M5445	Janoshik	2026-Q1	98.42	5.82	97.2	Buyer-sourced	0	FAIL
AX-2025-021111	Tirzepatide	QST-2409-K5786	Nordanalyt	2024-Q4	98.84	6.45	89.5	Supplier-supplied	1	MARGINAL
AX-2025-021112	Tirzepatide	QST-2409-K5786	Janoshik	2024-Q4	98.02	5.78	98.6	Buyer-sourced	0	PASS
AX-2024-005327	Tirzepatide	QST-2409-K5786	Janoshik	2024-Q4	98.90	6.81	97.8	Supplier-supplied	0	PASS
AX-2024-005331	Tirzepatide	QST-2409-K5786	PeptideMeter	2024-Q4	97.53	5.57	—	Buyer-sourced	0	PASS
AX-2024-005330	Tirzepatide	QST-2409-K5786	Medutest	2024-Q4	97.89	6.25	91.3	Buyer-sourced	0	PASS
AX-2024-005332	Tirzepatide	QST-2409-K5786	Nordanalyt	2024-Q4	98.40	6.32	—	Buyer-sourced	0	PASS
AX-2024-005329	Tirzepatide	QST-2409-K5786	PeptideMeter	2024-Q4	98.10	6.65	—	Buyer-sourced	0	PASS